Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–156 of 156 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High-dose influenza virus vaccine Clear all
Completed Phase 2 Interventional

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

NCT01037205
View directory record Official record
Conditions
Influenza
Interventions
DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
42
States / cities
Carmichael, California • Chula Vista, California • La Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 13, 2026, 4:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

NCT04484532
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
40 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 13, 2026, 4:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

FLUAD® vs. Fluzone® High-Dose Study

NCT03183908
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug, Adverse Drug Event
Interventions
FLUAD®, Fluzone® High-Dose
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
757 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 13, 2026, 4:23 PM EDT
Completed Phase 4 Interventional Results available

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

NCT04080531
View directory record Official record
Conditions
Plasma Cell Neoplasm
Interventions
Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 13, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

NCT03698279
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 13, 2026, 4:23 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

NCT00976027
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
9,172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
96
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 13, 2026, 4:23 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

NCT02500680
View directory record Official record
Conditions
Influenza, Human
Interventions
MER4101, Inactivated Influenza Vaccine
Biological
Lead sponsor
Nova Immunotherapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 13, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

NCT02233816
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 13, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

NCT04622592
View directory record Official record
Conditions
Influenza
Interventions
Instramuscular vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
14
States / cities
Huntsville, Alabama • Chandler, Arizona • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 13, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

NCT01068912
View directory record Official record
Conditions
Influenza
Interventions
Favipiravir, Placebo comparator
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
20 Years to 80 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
148
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 13, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

NCT05553301
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Rolling Hills Estates, California • San Diego, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 13, 2026, 4:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02258334
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 13, 2026, 4:23 PM EDT